One hundred and eight participants are included in the present study; 25 with active disease (AD), 38 in disease remission (DR), 10 with membranous nephropathy (MM), five with minimal change disease (MCD), 10 with immunoglobulin A nephropathy (IgA), 10 with pre-renal acute kidney injury (AKI) in the context of infection and 10 healthy controls (HC). The gene discussed is CD79A; the disease is Miyoshi myopathy.